Qiagen (NYSE:QGEN) Price Target Raised to $55.00

Qiagen (NYSE:QGEN) had its price target increased by JPMorgan Chase & Co. from $50.00 to $55.00 in a research report report published on Wednesday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

A number of other brokerages have also recently weighed in on QGEN. Kepler Capital Markets set a $38.60 price objective on Qiagen and gave the company a “hold” rating in a research note on Thursday, June 25th. UBS Group initiated coverage on Qiagen in a report on Wednesday, September 9th. They issued a “neutral” rating and a $47.00 price objective on the stock. Jefferies Financial Group reissued a “buy” rating and set a $48.00 target price on shares of Qiagen in a research note on Thursday, August 6th. Barclays set a $40.00 target price on Qiagen and gave the company an “equal weight” rating in a report on Friday, August 7th. Finally, Stifel Nicolaus set a $40.00 target price on Qiagen in a research report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, Qiagen presently has a consensus rating of “Hold” and an average target price of $43.93.

Qiagen Price Performance

Shares of QGEN opened at $46.17 on Wednesday. The firm has a 50-day simple moving average of $43.83 and a two-hundred day simple moving average of $40.34. The stock has a market cap of $9.52 billion, a PE ratio of 19.06, a P/E/G ratio of 4.60 and a beta of 0.61. Qiagen has a 1-year low of $32.53 and a 1-year high of $57.81. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.85 and a quick ratio of 2.31.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, topping the consensus estimate of $0.60 by $0.02. The firm had revenue of $535.04 million for the quarter, compared to analyst estimates of $527.50 million. Qiagen had a net margin of 19.49% and a return on equity of 14.47%. The business’s revenue for the quarter was up .2% compared to the same quarter last year. During the same period in the prior year, the business posted $0.60 EPS. Qiagen has set its FY 2026 guidance at 2.430- EPS. As a group, analysts forecast that Qiagen will post 2.43 EPS for the current year.

Institutional Investors Weigh In On Qiagen

Hedge funds have recently added to or reduced their stakes in the business. Engineers Gate Manager LP grew its stake in shares of Qiagen by 107.7% in the second quarter. Engineers Gate Manager LP now owns 74,567 shares of the company’s stock worth $2,916,000 after acquiring an additional 38,658 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new stake in shares of Qiagen during the first quarter worth $2,518,000. Baader Bank Aktiengesellschaft acquired a new stake in shares of Qiagen in the first quarter valued at $1,368,000. Public Employees Retirement System of Ohio acquired a new stake in shares of Qiagen in the second quarter valued at $2,836,000. Finally, WINTON GROUP Ltd acquired a new stake in shares of Qiagen in the second quarter valued at $1,423,000. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Qiagen Company Profile

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample technologies, molecular testing solutions and bioinformatics products. The company develops tools that help researchers and healthcare professionals isolate, analyze and interpret biological materials, including DNA, RNA and proteins.

Its portfolio includes laboratory kits and instruments for sample preparation, polymerase chain reaction (PCR), next-generation sequencing, genotyping and molecular diagnostics. QIAGEN also provides digital and bioinformatics solutions used to manage and analyze biological data.